Editas Medicine, Inc.

( )
EDIT After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen Inc.
CELGCelgene Corporation
GILDGilead Sciences, Inc.
BIIBBiogen Inc.
NKTRNektar Therapeutics
REGNRegeneron Pharmaceuticals, Inc.
VRTXVertex Pharmaceuticals Incorporated
ALXNAlexion Pharmaceuticals, Inc.
ILMNIllumina, Inc.
AAgilent Technologies, Inc.
EXASExact Sciences Corporation
INCYIncyte Corporation
BLUEBluebird Bio, Inc.
SRPTSarepta Therapeutics, Inc.
BMRNBioMarin Pharmaceutical Inc.

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editting technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.^ ^ ^